

audience data service competitors of Epsilon, thereby making it harder for them to compete or even pushing them out of the market completely. The Acquisition would also likely result in Publicis having the ability and incentive to deny or degrade access to LiveRamp's services for audience data service providers that compete with Epsilon. This type of foreclosure could raise Epsilon's competitors' costs by forcing them to turn to less preferred data connectivity providers with smaller scale and reach and/or spend resources on building out additional data connections.

In addition, the Acquisition would likely result in Publicis having the ability and incentive to appropriate competitively sensitive LiveRamp client data for the benefit of Publicis's media agency services and its own clients. As a result, clients that otherwise prefer the media agency services of competing ad agencies may be pressured to switch to Publicis in order to avoid the competitive harm of data appropriation. This may substantially lessen competition in the market for U.S. media agency services considering Publicis's already large share of net new business awarded over the past few years.

Absent the protections of the Consent Agreement, after the Acquisition, Publicis would likely have the ability and incentive to foreclose by denying or degrading access to LiveRamp's services or by otherwise making decisions to undermine and disadvantage their competitors in the markets for audience data services and media agency services. Publicis would also gain access to competitively sensitive information relating to its competitors and exploit it to its own advantage.

VI. The Order and the Order To Maintain Assets

The Order and the Order to Maintain Assets effectively remedy the Acquisition's likely anticompetitive effects in both the market for audience data services and the market for media agency services by requiring that LiveRamp continue to operate as a neutral platform for all current and future customers by: (1) providing non-discriminatory access to and support for LiveRamp's standalone products and services; (2) preserving access to and support for LiveRamp's standalone products and services, including any access or support required from Publicis; and (3) supporting non-discriminatory interoperability between LiveRamp's standalone products and services and non-Publicis third-party platforms. The non-discrimination

prohibitions of the Order apply to any potential discriminatory conduct affecting access, customer and technical support, price, product functionality, technology, and product and platform choice.

The Order requires Publicis to establish firewalls to ensure that Publicis does not access or use LiveRamp customer data and confidential business information that it receives from a customer's use of LiveRamp's standalone products and services, and that Publicis does not transfer or commingle such data for the benefit or development of Publicis products and services. The Order also requires that certain employees who receive any LiveRamp customer confidential business information receive training regarding the restrictions on the use and dissemination of such information.

The Order provides that Publicis shall appoint an independent industry-standard auditor to audit Publicis's compliance with the Order every six months for the first two years after the date of Acquisition, and then once a year thereafter. Copies of the audit will be provided to the Commission. LiveRamp customers may also request an audit, up to once a year, and the Order requires Publicis to conduct an audit of its compliance with the Order's obligations for that customer. The Order also provides for third-party mediation in the event of any disputes arising or relating to noncompliance with the Order.

Finally, the Order specifies that it will terminate five years from the date it is issued.

The purpose of this analysis is to facilitate public comment on the proposed Consent Agreement, and it is not intended to constitute an official interpretation of the proposed Consent Agreement or to modify its terms in any way.

By direction of the Commission.

Joel Christie,
Acting Secretary.

[FR Doc. 2026-21659 Filed 10-22-26; 8:45 am]

BILLING CODE 6750-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

[Office of Management and Budget #: 0970-0114]

Proposed Information Collection Activity; Child Care and Development Fund Plan Preprint for States/Territories for Federal Fiscal Year (FFY) 2028–2030 (ACF–118) and extension of Child Care and Development Fund Plan Preprint for States/Territories for FFY 2025–2027

AGENCY: Office of Child Care, Administration for Children and Families, U.S. Department of Health and Human Services.

ACTION: Request for public comments.

SUMMARY: The Administration for Children and Families (ACF) is requesting an extension without changes of the form ACF–118: Child Care and Development Fund (CCDF) Plan Preprint for States/Territories for FFY 2025–2027 (Office of Management and Budget #: 0970–0114, expiration March 31, 2027), and an additional 3-year extension of the form ACF–118: CCDF Plan Preprint for States/Territories for FFY 2028–2030. There are changes requested to the form ACF–118: CCDF Plan Preprint for States/Territories for FFY 2028–2030 to reduce burden, streamline questions, reduce data entry, and strengthen program integrity.

DATES: Comments due December 22, 2026.

ADDRESSES: In compliance with the requirements of the Paperwork Reduction Act of 1995, ACF is soliciting public comment on the specific aspects of the information collection described above. You can obtain copies of the proposed collection of information and submit comments by emailing infocollection@acf.hhs.gov. Identify all requests by the title of the information collection.

SUPPLEMENTARY INFORMATION:

Description: The CCDF Plan (the Plan) for states and territories is required from each CCDF Lead Agency in accordance with section 658E of the Child Care and Development Block Grant Act of 1990 (CCDBG Act), as amended, CCDBG Act of 2014 (Pub. L. 113–186), and 42 U.S.C. 9858. The Plan, submitted on the ACF–118, is required triennially, and remains in effect for 3 years. These Plans are the applications for CCDF funds and provide ACF and the public with a description of and assurance about the

states' and territories' CCDF program and child care services.

At this time, ACF's Office of Child Care (OCC) is proposing an extension of the approval of the currently approved CCDF Plan Preprint for FFY 2025–2027 to allow states and territories to

continue to submit amendments through September 30, 2027, as required. There are no changes proposed to the FFY 2025–2027 Plan Preprint. In addition, OCC is requesting comments on the proposed CCDF Plan

Preprint for FFY 2028–2030. Updates were made to simplify and reduce questions, reduce burden, and strengthen program integrity.

Respondents: State and Territory Lead Agencies.

ANNUAL BURDEN ESTIMATES

Instrument	Total number of respondents	Total number of responses per respondent	Average burden hours per response	Total burden hours	Annual burden hours
Child Care and Development Fund for States and Territories (ACF–118)	56	1	32	1,792	597

Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Authority: Pub. L. 113–186 and 42 U.S.C. 9858

Samantha L. Illangasekare,
ACF/OPRE Certifying Officer.

[FR Doc. 2026–21703 Filed 10–22–26; 8:45 am]

BILLING CODE 4184–87–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–N–7130]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Accreditation Scheme for Conformity Assessment Program

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget

(OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Submit written comments (including recommendations) on the collection of information by November 23, 2026.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to <https://www.reginfo.gov/public/do/PRAMain>. Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910–0889. Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT:

Amber Barrett, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–8867, PRAStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Accreditation Scheme for Conformity Assessment Program

OMB Control Number 0910–0889—Reinstatement

The FDA Reauthorization Act of 2017 (FDARA), enacted as part of the Medical Device User Fee Amendments of 2017 (MDUFA IV), amended section 514 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) by adding Section 514(d). Section 514(d) directed FDA to establish a pilot program under which testing laboratories may be accredited by accreditation bodies meeting criteria specified by FDA to assess whether a device conforms with certain FDA-

recognized consensus standards. The FDA User Fee Reauthorization Act of 2022 (FUFRA), enacted as part of the Medical Device User Fee Amendments of 2022 (MDUFA V), subsequently directed FDA to conclude the pilot phase and continue the Accreditation Scheme for Conformity Assessment (ASCA) as an ongoing program.

FDA generally accepts determinations by ASCA-accredited testing laboratories that a device conforms with an eligible standard unless FDA determines that a particular conformity determination should not be accepted.

The statute provides that FDA may review determinations made by accredited testing laboratories, including by conducting periodic audits of such determinations or reviewing the processes of accreditation bodies or testing laboratories.

Following such a review, or if FDA becomes aware of information materially bearing on safety or effectiveness of a device assessed by an ASCA-accredited testing laboratory, FDA may take additional measures as determined appropriate. Such measures may include suspension or withdrawal of a testing laboratory's ASCA Accreditation, withdrawal of an accreditation body's ASCA Recognition, or a request for additional information regarding a specific device.

FDA issued the final guidance “The Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program” in September 2020 to discuss the goals and implementation of the voluntary ASCA Pilot Program. In September 2024, FDA issued three draft guidance documents intended to update the ASCA Program based on lessons learned during the pilot phase and support its continued operation as an ongoing program.

The establishment of the goals, scope, procedures, and a suitable framework for the voluntary ASCA Program supports the Agency's continued efforts to use its scientific resources effectively